MDoloris and PPRS Launch ANI Guardian

Although the comfort of patients under anesthesia can be optimally assured in the operating room or in intensive care thanks to nociception (systemic pain) monitoring equipment, the absence of robust solutions for other non-communicating patients, whether in palliative care, with disabilities or suffering from diseases such as autism or Alzheimer’s disease, represents a major challenge for health professionals, families and public authorities.
 
MDoloris and PPRS, two French MedTechs, have collaborated to launch ANI Guardian, a new easy-to-use tool for measuring the well-being and comfort of non-communicating patients developed according to the highest scientific, medical and regulatory standards.
 
The ANI technology is the result of 23 years of research carried out in an Inserm laboratory (L’Institut National de la Santé et de la Recherche Médicale) at the University Hospital of Lille.
 
Since 2010, this global innovation with 3 patents has been exclusively promoted by MDoloris Medical Systems on the healthcare market. With more than 200 international publications, the reliability of this new physiological measurement is widely validated. Hospital anesthesiologists use it every day in university hospitals to measure the pain suffered by the body of patients under general anesthesia during surgery or when they are narcotized in the intensive care unit. More than 400,000 patients, 30% of whom are new-borns, have already benefited from the added value of MDoloris technology.
 
Thanks to the ANI, which continuously measures the activity of the autonomic nervous system in its parasympathetic component, it is now possible to avoid and prevent adverse effects due to overdose (respiratory depression, bradycardia, nausea, vomiting, intense pain when waking) or underdose (instability of the body and inflammatory response).
 
In 2020, the COVID crisis highlighted the importance of this new technology for serious COVID patients in intensive care. For several years, other medical disciplines have been interested in ANI technology for conscious patients unable to communicate. In particular autistic people, people with multiple disabilities, end-of-life care, patients suffering from serious cognitive disorders (e.g. Alzheimer’s).
 
For these patients, and for the first time ever, ANI technology is able to continuously, reliably and non-invasively answer the question: what is the level of comfort and well-being of these patients? Is it well-optimized? The partnership with PPRS allows MDoloris to offer an easy-to-use and reliable solution where a connected bracelet and a smartphone app will meet this need of the medical community and families.
 
The device provides a recording of the patient’s pulse measured by plethysmography of superior quality to consumer devices thanks to the proprietary signal processing algorithms and the combined ergonomics of its mechanics and its textile armband.
 
The device, which started its development in 2014 in partnership with Pr Régis Logier from the CIC-IT of the CHRU Lille, Pr Régis Lengellé from the University of Technology of Troyes and the “Cluster Nord Excellence” (composed of Bluegriot, RD2, Toptexcube, ACPM and Prestocab) obtained the medical CE marking for sleep monitoring in 2020 marketed under the Somno-Art brand.
 
The technology on which the cardiac signal capture software is based is patented in the European Union, Canada, Japan, China, Brazil, and Mexico.
 
PPRS aims to obtain the medical CE marking in 2023.